GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer

GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer

Triple negative breast cancer is a deadly form of breast cancer with limited therapeutic options. Here the authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level as a biomarker of sensitivity to anti-GLUT1 therap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Qin Wu, Wail ba-alawi, Genevieve Deblois, Jennifer Cruickshank, Shili Duan, Evelyne Lima-Fernandes, Jillian Haight, Seyed Ali Madani Tonekaboni, Anne-Marie Fortier, Hellen Kuasne, Trevor D. McKee, Hassan Mahmoud, Michelle Kushida, Sarina Cameron, Nergiz Dogan-Artun, WenJun Chen, Yan Nie, Lan Xin Zhang, Ravi N. Vellanki, Stanley Zhou, Panagiotis Prinos, Bradly G. Wouters, Peter B. Dirks, Susan J. Done, Morag Park, David W. Cescon, Benjamin Haibe-Kains, Mathieu Lupien, Cheryl H. Arrowsmith
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/130018a3112a40a29ff505012c3352a4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Triple negative breast cancer is a deadly form of breast cancer with limited therapeutic options. Here the authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level as a biomarker of sensitivity to anti-GLUT1 therapy.

Ejemplares similares